Cargando…
Discontinuation of carbamazepine due to concerns of long‐term consequences of enzyme induction
OBJECTIVE: Treatment with carbamazepine (CBZ), a potent enzyme inducer, is known to affect the lipid profile, steroid, and vitamin D metabolism. Consequently, it has been postulated that patients on CBZ should be switched to noninducing antiepileptic drugs (AEDs). However, little is known about the...
Autores principales: | Mäkinen, Jussi, Rainesalo, Sirpa, Raitanen, Jani, Saarinen, Jukka, Sandell, Satu, Peltola, Jukka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119761/ https://www.ncbi.nlm.nih.gov/pubmed/30187004 http://dx.doi.org/10.1002/epi4.12227 |
Ejemplares similares
-
Treatment outcomes in women with idiopathic generalized epilepsy
por: Kiiski, Rebecca, et al.
Publicado: (2021) -
Transition from oxcarbazepine to eslicarbazepine acetate: A single center study
por: Mäkinen, Jussi, et al.
Publicado: (2017) -
Improving the effectiveness of ANT DBS therapy for epilepsy with optimal current targeting
por: Järvenpää, Soila, et al.
Publicado: (2020) -
Elevated IL-6 plasma levels are associated with GAD antibodies-associated autoimmune epilepsy
por: Basnyat, Pabitra, et al.
Publicado: (2023) -
Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy
por: Hersi, Hire, et al.
Publicado: (2022)